Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.
Metrics to compare | ZELA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipZELAPeersSector | |
---|---|---|---|---|
P/E Ratio | −82.4x | −1.3x | −0.6x | |
PEG Ratio | −2.25 | 0.18 | 0.00 | |
Price / Book | 6.2x | 7.2x | 2.6x | |
Price / LTM Sales | 159.4x | 6.9x | 3.2x | |
Upside (Analyst Target) | 22.6% | 64.1% | 46.3% | |
Fair Value Upside | Unlock | 7.0% | 6.1% | Unlock |